newswire, breaking biotechnology and pharma news

Monday, January 25, 2021

Investor Ideas #Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. (OTC: $SIGY) Discusses Treatment of Life-Threatening Conditions Induced by #Cytokine Storm Syndrome; @Sigyn_inc





Investor Ideas #Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. (OTC: $SIGY) Discusses Treatment of Life-Threatening Conditions Induced by #Cytokine Storm Syndrome; @Sigyn_inc


Point Roberts WA, Delta BC, January 25, 2021 -, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today’s special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) Chairman and CEO, Jim Joyce.



Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc. (NASDAQ: AEMD)


Listen to today’s Podcast:


Read this in full at


Listen to Investor Ideas podcasts on Spotify


Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, “Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections.  It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion.”  Mr Joyce added that: “Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies.”


Mr. Joyce further discussed how the limitations of single-target drugs have created an increased interest in extracorporeal blood purification technologies that can address a broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are limited to a single Cytokine target.


Continued: “We really see two pioneering devices and they happen to be associated with public companies. One is the CytoSorb device from CytoSorbents Corporation (NASDAQ: CTSO) which has a market value of approximately $400 million. This device is designed to reduce the presence of a broad-spectrum of inflammatory cytokines from circulation.”


Continued: “The other device is the Toraymyxin Device which is a product of Toray Industries, Inc. (3402.T) based in Japan.  This is one of about several products from Toray that drives a market value of about $10 billion. The Toraymyxin product eliminates circulating endotoxins, which is a potent activator of the cytokine storm.”


Continued: “However, it does not address inflammatory Cytokines.  Inversely, CytoSorb addresses inflammatory Cytokines but doesn't address endotoxin. So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory Cytokine cargos throughout the circulatory system (OTCMarkets: SIGY).”


Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California, USA. Their focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their mission is to save lives.


Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.


Joyce also discusses his previous leadership role at Aethlon Medical, Inc. (NASDAQ: AEMD) where he oversaw the development of the Hemopurifier to treat life-threatening viral infections and address tumor-derived exosomes in cancer patients as a great experience prior to founding Sigyn Therapeutics, Inc.


To learn more, visit  or

About - News that Inspires Big Investing Ideas is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The podcasts are also available on iTunes,  Spotify, Tunein, Stitcher,, iHeartRadio and Google Play Music.

Visit the Podcast page at

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more about publishing your news release and our other news services on the newswire and Global investors must adhere to regulations of each country. Please read privacy policy:

Follow us on Twitter

Follow us on Facebook

Follow us on YouTube

Download our Mobile App for iPhone and Android 

Join our Investor Club



800-665-0411 - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks


No comments:

Post a Comment